-
There is a shortage of production capacity in the cell and gene therapy space. Can Orgenesis provide the cure?
The new generation of biopharma aims to cure cancers and genetic diseases. The old generation provides maintenance programs for minimizing damage. Having talked with CEO Vered Caplan (again) she’s got me quite convinced this business will be a services champion for “the new generation” of biopharma. Orgenesis (ORGS, NASDAQ) $1.34 per share | Market Cap $33 million Orgenesis is…
